Get the Stockscreener App
67.00
2.98%
-2.06
After Hours:
67.10
0.10
+0.15%
Viking Therapeutics Inc stock is currently priced at $67.00, with a 24-hour trading volume of 4.14M.
It has seen a -2.98% decreased in the last 24 hours and a +0.80% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $71.45 pivot point. If it approaches the $66.01 support level, significant changes may occur.
Previous Close:
$69.06
Open:
$69.99
24h Volume:
4.14M
Market Cap:
$7.39B
Revenue:
-
Net Income/Loss:
$-93.72M
P/E Ratio:
-72.04
EPS:
-0.93
Net Cash Flow:
$-54.87M
1W Performance:
-9.02%
1M Performance:
+0.80%
6M Performance:
+494.50%
1Y Performance:
+174.48%
1D Range:
$66.68
$71.09
52W Range:
$8.28
$99.41
Viking Therapeutics Inc Stock (VKTX) Company Profile
Name
Viking Therapeutics Inc
Sector
Industry
Phone
858-704-4660
Address
12340 El Camino Real, Suite 250, San Diego, CA
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-31-23 | Resumed | ROTH MKM | Buy |
| Mar-28-23 | Reiterated | Maxim Group | Buy |
| Mar-17-23 | Initiated | Stifel | Buy |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-05-20 | Initiated | BMO Capital Markets | Outperform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| May-01-20 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-25-19 | Initiated | Stifel | Buy |
| Mar-29-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-14-19 | Reiterated | Maxim Group | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Nov-19-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-18-18 | Reiterated | Maxim Group | Buy |
| Sep-18-18 | Reiterated | Raymond James | Outperform |
| Jul-20-18 | Initiated | SunTrust | Buy |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-01-18 | Reiterated | Laidlaw | Buy |
| May-31-18 | Reiterated | Maxim Group | Buy |
| Mar-26-18 | Resumed | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | Maxim Group | Buy |
| Nov-21-17 | Initiated | ROTH Capital | Buy |
View All
Viking Therapeutics Inc Stock (VKTX) Latest News
Emerging Leaders: Roche, Viking Therapeutics In The Obesity Treatment Race (OTCMKTS:RHHBY) - Seeking Alpha
Seeking Alpha
Smart Money Is Betting Big In VKTX Options - Viking Therapeutics (NASDAQ:VKTX) - Benzinga
Benzinga
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
Zacks Investment Research
Is Viking Therapeutics Stock a Buy? - Yahoo Finance
Yahoo Finance
MSN - MSN
MSN
Viking Therapeutics posts positive results for oral weight-loss drug. Analysts remain unanimous the stock's a buy. - MSN
MSN
Viking Therapeutics Inc Stock (VKTX) Financials Data
Viking Therapeutics Inc (VKTX) Net Income 2024
VKTX net income (TTM) was -$93.72 million for the quarter ending March 31, 2024, a -29.64% decrease year-over-year.
Viking Therapeutics Inc (VKTX) Cash Flow 2024
VKTX recorded a free cash flow (TTM) of -$54.87 million for the quarter ending March 31, 2024, a +12.23% increase year-over-year.
Viking Therapeutics Inc (VKTX) Earnings per Share 2024
VKTX earnings per share (TTM) was -$0.93 for the quarter ending March 31, 2024, a +2.11% growth year-over-year.
Viking Therapeutics Inc Stock (VKTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ZANTE GREG | Chief Financial Officer |
May 03 '24 |
Option Exercise |
4.86 |
34,249 |
166,285 |
241,610 |
| ZANTE GREG | Chief Financial Officer |
May 03 '24 |
Sale |
74.69 |
66,756 |
4,986,008 |
174,854 |
| Mancini Marianna | Chief Operating Officer |
May 01 '24 |
Option Exercise |
6.18 |
281,425 |
1,740,575 |
629,933 |
| Mancini Marianna | Chief Operating Officer |
May 01 '24 |
Sale |
78.66 |
281,425 |
22,136,474 |
348,508 |
| Lian Brian | President & CEO |
Feb 09 '24 |
Sale |
29.90 |
45,000 |
1,345,500 |
2,139,882 |
| Lian Brian | President & CEO |
Feb 08 '24 |
Option Exercise |
3.76 |
189,079 |
711,367 |
2,404,882 |
| Rouan Sarah Kathryn | Director |
Feb 08 '24 |
Option Exercise |
8.32 |
25,000 |
208,000 |
25,000 |
| Lian Brian | President & CEO |
Feb 08 '24 |
Sale |
26.87 |
269,079 |
7,230,784 |
2,184,882 |
| Rouan Sarah Kathryn | Director |
Feb 08 '24 |
Sale |
28.05 |
25,000 |
701,250 |
0 |
| Lian Brian | President & CEO |
Jan 31 '24 |
Option Exercise |
1.23 |
85,000 |
104,550 |
2,349,882 |
About Viking Therapeutics Inc
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
0.77%
1.20%
Cap:
|
Volume (24h):